Search Journal-type in search term and press enter
Southwest Pulmonary and Critical Care Fellowships

Critical Care

Last 50 Critical Care Postings

(Most recent listed first. Click on title to be directed to the manuscript.)

October 2024 Critical Care Case of the Month: Respiratory Failure in a
   Patient with Ulcerative Colitis
July 2024 Critical Care Case of the Month: Community-Acquired
   Meningitis
April 2024 Critical Care Case of the Month: A 53-year-old Man Presenting
   with Fatal Acute Intracranial Hemorrhage and Cryptogenic Disseminated
   Intravascular Coagulopathy
Delineating Gastrointestinal Dysfunction Variants in Severe Burn Injury
   Cases: A Retrospective Case Series with Literature Review
Doggonit! A Classic Case of Severe Capnocytophaga canimorsus Sepsis
January 2024 Critical Care Case of the Month: I See Tacoma
October 2023 Critical Care Case of the Month: Multi-Drug Resistant
   K. pneumoniae
May 2023 Critical Care Case of the Month: Not a Humerus Case
Essentials of Airway Management: The Best Tools and Positioning for 
   First-Attempt Intubation Success (Review)
March 2023 Critical Care Case of the Month: A Bad Egg
The Effect of Low Dose Dexamethasone on the Reduction of Hypoxaemia
   and Fat Embolism Syndrome After Long Bone Fractures
Unintended Consequence of Jesse’s Law in Arizona Critical Care Medicine
Impact of Cytomegalovirus DNAemia Below the Lower Limit of
   Quantification: Impact of Multistate Model in Lung Transplant Recipients
October 2022 Critical Care Case of the Month: A Middle-Aged Couple “Not
   Acting Right”
Point-of-Care Ultrasound and Right Ventricular Strain: Utility in the
   Diagnosis of Pulmonary Embolism
Point of Care Ultrasound Utility in the Setting of Chest Pain: A Case of
   Takotsubo Cardiomyopathy
A Case of Brugada Phenocopy in Adrenal Insufficiency-Related Pericarditis
Effect Of Exogenous Melatonin on the Incidence of Delirium and Its 
   Association with Severity of Illness in Postoperative Surgical ICU Patients
Pediculosis As a Possible Contributor to Community-Acquired MRSA
   Bacteremia and Native Mitral Valve Endocarditis
April 2022 Critical Care Case of the Month: Bullous Skin Lesions in
   the ICU
Leadership in Action: A Student-Run Designated Emphasis in
   Healthcare Leadership
MSSA Pericarditis in a Patient with Systemic Lupus
   Erythematosus Flare
January 2022 Critical Care Case of the Month: Ataque Isquémico
   Transitorio in Spanish 
Rapidly Fatal COVID-19-associated Acute Necrotizing
   Encephalopathy in a Previously Healthy 26-year-old Man 
Utility of Endobronchial Valves in a Patient with Bronchopleural Fistula in
   the Setting of COVID-19 Infection: A Case Report and Brief Review
October 2021 Critical Care Case of the Month: Unexpected Post-
   Operative Shock 
Impact of In Situ Education on Management of Cardiac Arrest after
   Cardiac Surgery
A Case and Brief Review of Bilious Ascites and Abdominal Compartment
   Syndrome from Pancreatitis-Induced Post-Roux-En-Y Gastric Remnant
   Leak
Methylene Blue Treatment of Pediatric Patients in the Cardiovascular
   Intensive Care Unit
July 2021 Critical Care Case of the Month: When a Chronic Disease
   Becomes Acute
Arizona Hospitals and Health Systems’ Statewide Collaboration Producing a 
   Triage Protocol During the COVID-19 Pandemic
Ultrasound for Critical Care Physicians: Sometimes It’s Better to Be Lucky
   than Smart
High Volume Plasma Exchange in Acute Liver Failure: A Brief Review
April 2021 Critical Care Case of the Month: Abnormal Acid-Base Balance
   in a Post-Partum Woman
First-Attempt Endotracheal Intubation Success Rate Using A Telescoping
   Steel Bougie 
January 2021 Critical Care Case of the Month: A 35-Year-Old Man Found
   Down on the Street
A Case of Athabaskan Brainstem Dysgenesis Syndrome and RSV
   Respiratory Failure
October 2020 Critical Care Case of the Month: Unexplained
   Encephalopathy Following Elective Plastic Surgery
Acute Type A Aortic Dissection in a Young Weightlifter: A Case Study with
   an In-Depth Literature Review
July 2020 Critical Care Case of the Month: Not the Pearl You Were
   Looking For...
Choosing Among Unproven Therapies for the Treatment of Life-Threatening
   COVID-19 Infection: A Clinician’s Opinion from the Bedside
April 2020 Critical Care Case of the Month: Another Emerging Cause
   for Infiltrative Lung Abnormalities
Further COVID-19 Infection Control and Management Recommendations for
   the ICU
COVID-19 Prevention and Control Recommendations for the ICU
Loperamide Abuse: A Case Report and Brief Review
Single-Use Telescopic Bougie: Case Series
Safety and Efficacy of Lung Recruitment Maneuvers in Pediatric Post-
   Operative Cardiac Patients
January 2020 Critical Care Case of the Month: A Code Post Lung 
   Needle Biopsy
October 2019 Critical Care Case of the Month: Running Naked in the
   Park

 

For complete critical care listings click here.

The Southwest Journal of Pulmonary and Critical Care publishes articles directed to those who treat patients in the ICU, CCU and SICU including chest physicians, surgeons, pediatricians, pharmacists/pharmacologists, anesthesiologists, critical care nurses, and other healthcare professionals. Manuscripts may be either basic or clinical original investigations or review articles. Potential authors of review articles are encouraged to contact the editors before submission, however, unsolicited review articles will be considered.

------------------------------------------------------------------------------------

Tuesday
Oct182011

Critical Care Review: the High Price of Sugar

Reference as: Robbins RA, Singarajah CU. Critical care review: the high price of sugar. Southwest J Pulm Crit Care 2011;3: 78-86. (Click here for PDF version)

Richard A. Robbins, MD

Clement U. Singarajah, MD

The Phoenix Pulmonary and Critical Care Research and Education Foundation, Phoenix, AZ

Abstract

The intensive control of blood glucose had been proposed to be important in increasing survival in the intensive care unit (ICU) despite only one positive randomized trial. The concept was supported by guidelines released by several regulatory organizations including the Joint Commission of Healthcare Organizations and the Institute of Healthcare Improvement. However, the large, randomized, multi-center NICE-SUGAR trial published in 2009 showed tight control of glucose in the ICU is actually hazardous with a 14% increase in mortality. The historical basis and data used to support intense control of glucose in the ICU are reviewed and illustrate the harm that can result when guidelines are based on weak evidence.

Intensive Control of Glucose in Diabetes

Diabetes has long been associated with vascular complications. These are divided into microvascular complications (retinopathy, nephropathy, and neuropathy) and macrovascular complications (coronary artery disease, stroke, and peripheral vascular disease). The concept that intense control of glucose results in improved vascular outcomes in diabetes dates back decades but has been plagued with controversy. The University Group Diabetes Program Study (UGDPS), which began in 1959, was designed to evaluate the relationship between blood sugar control and vascular complications in patients with newly diagnosed type II diabetes. The investigators found that control of blood sugar levels was ineffective in preventing the micro- and macrovascular complications associated with diabetes, regardless of the type of therapy (1). This prompted the American Diabetes Association (ADA) and the American Medical Association to withdrawn their support of UDGPS (2). In 1978, at a meeting of diabetes researchers, clinicians, and epidemiologists from the ADA, the National Institutes of Health (NIH), the Centers for Disease Control, and various university centers, it was concluded that there was “no definite evidence that treatment to regulate blood sugar levels is effective beyond relieving symptoms and controlling acute metabolic disturbances” (2).

This controversy prompted the NIH to organize the Diabetes Control and Complications Trial. This was a large, multi-center, randomized study which compared intensive to conventional treatment in preventing vascular complications in insulin-dependent, type I diabetics. Published in 1993, the results of this trial demonstrated that intensive therapy effectively delayed the onset and slowed the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes (3). However, the mortality rate, incidence of macrovascular complications, and incidence of diabetic ketoacidosis were not significantly reduced. Weight gain and episodes of hypoglycemia were significantly more common in the intensive therapy group.

Published in 1998 but started in 1977, the UK Prospective Diabetes Study (UKPDS) was designed to determine if intensive blood glucose control reduced the risk of micro- or macrovascular complications in type II diabetes (4). This study is important since over 90% of adult diabetics, including the majority of diabetics in an adult ICU, have type II diabetes. This large, multi-center, randomized study compared conventional therapy with diet alone to an intense glucose control with diet and either a sulphonylurea (chlorpropamide, glibenclamide, or glipizide) or insulin. The goals of the study were to maintain fasting blood glucose of less than 270 mg/dL (15 mmol/L) in the conventional group and less than 108 mg/dL (6 mmol/L) in the intensive control group. Consistent with the blood sugar goals of the study, the hemoglobin A1C was reduced in the intensive therapy group compared to the conventional group (7.0% vs. 7.9%, p<0.05). The results in this study of type II diabetics were similar to the Diabetes Control and Complications Trial in type I diabetics. Microvascular complications, particularly retinal complications, were significantly reduced in the intensive therapy group but macrovascular complications were not. Mortality was not reduced and hypoglycemia and weight gain were more common in the intensive therapy group.

Intensive Control of Blood Glucose in the ICU

Hyperglycemia associated with insulin resistance is common in critically ill patients, even those who have not previously had diabetes (5-7). It had been reported that pronounced hyperglycemia might lead to complications. For example, studies reported that in acute myocardial infarction therapy to maintain blood glucose below 215 mg /dL (11.9 mmol/L) improved long-term outcomes (8-10). Furthermore, high serum levels of insulin-like growth factor-binding protein 1, which reflect insulin resistance, increase the risk of death (11, 12).

Spurred by the above data and the overwhelming opinion of diabetes experts that intensive control of glucose improves outcomes in diabetes and should in the ICU, van den Berge et al. (13) compared intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg/dL) to conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg/dL and maintenance of glucose at a level between 180 and 200 mg/dL) in ICU patients. The study was large with 1548 subjects but was a single center study from a surgical intensive care unit with 63% of the patients post-cardiac surgery. Reported in 2001, the results showed that intensive insulin therapy reduced mortality during intensive care from 8.0 percent with conventional treatment to 4.6 percent (p<0.04). The benefit of intensive insulin therapy was attributable to its effect on mortality among patients who remained in the intensive care unit for more than five days (20.2 percent with conventional treatment, as compared with 10.6 percent with intensive insulin therapy; p=0.005).

The results of van den Berge’s original study were supported by a nonrandomized, single center study reported by Krinsley (14) in 2004. This study from a combined 14 bed medical/surgical ICU consisted of 800 consecutive patients after initiation of a intensive control protocol compared to 800 patients admitted immediately preceding initiation, i.e., a before and after design. The protocol involved intensive monitoring and treatment to maintain plasma glucose values lower than 140 mg/dL. Hospital mortality decreased 29.3% (p=0.002), and length of stay in the ICU decreased 10.8% (p=0.01) with intensive control of glucose. Despite the before and after comparison, some considered this single center study as confirmatory evidence for the mortality benefit of intensive glucose control.

It has been pointed out that van den Berge’s study had multiple limitations (15). Van den Berge’s 2001 study was a non-blinded, single center and including predominately patients after cardiac surgery, Other limitations included the unusual practices of most patients receiving intravenous glucose on arrival at the intensive care unit (ICU) at 200 to 300 g/d (the equivalent of 2-3 L of 10% glucose per day) and initiation of total parenteral nutrition, or enteral feeding, or combined feeding for all patients within 24 hours. Also, the mortality of cardiac surgery patients in the control group was 5.1% which is unacceptably high in most centers.

Kringsley’s study also had limitations (15). This was a single-center, retrospective, unblinded study and likely reflect a powerful Hawthorne effect (intense glucose control = investigator commitment and bedside presence, more tests, more attention, more patient visits, more interventions, and overall better care). Intensive insulin therapy comes at a substantial price: a greater than 6-fold increase in the risk of hypoglycemia and a marked increase in bedside nurse workload.

When many regulatory guidelines were initiated in the mid 2000’s,  not all data about glucose control and insulin in acute illness pointed to a benefit. The Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study with more than 1000 randomized patients with myocardial infarction to intense compared to conventional glucose control failed to show a mortality benefit (16). Similarly, the Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation (CREATE)-Estudios Cardiologicas Latin America Study Group (ECLA) study with over 20,000 randomized patients with myocardial infarction failed to show a benefit of a glucose, insulin and potassium infusion regimen compared to usual care (17).

Regulatory Guidelines

By 2005 the Joint Commission on Accreditation of Healthcare Organization (Joint Commission) and the Institute for Healthcare Improvement (IHI) recommended tight glucose control for the critically ill as a core quality of care measure for all U.S. hospitals (18). Furthermore, an international initiative by several professional societies, including the American Thoracic Society, promoted a care “bundle” for severe sepsis that also includes intensive glycemic control.

Concerns about Intensive Glucose Control in the ICU

The medical literature is rife with initially positive trials followed by studies with equivocal or negative trials and occasionally followed by studies with actual harm to patients (19). Intensive control of glucose is a good example of this progression in medical research.

In late 2005, editorials urged waiting on further studies before widespread implement of tight control of glucose as usual care in the ICU. Bellomo and Egi (17) recommended awaiting the results of two large multi-center, randomized trials of tight control of glucose in the ICU, the GluControl study and the NICE SUGAR study. Angus and Abraham (18) echoed the limitations of van den Berge’s study and also advocated caution in the widespread initiation of intensive glucose control in the ICU.

Van den Berge’s group that initially reported the positive results in surgical ICU patients followed their 2001 publication with a report of medical ICU patients in 2006 (20).  In this prospective, randomized study of adult patients admitted to the medical ICU, the authors were unable to reproduce the reduction of in-hospital mortality with intensive glucose control seen in their surgical ICU patients (40.0 vs. 37.3% mortality, p= 0.33). However, the authors reported a significant improvement in morbidity with a reduction in newly acquired kidney injury, accelerated weaning from mechanical ventilation, and accelerated discharge from the ICU and the hospital. However, among the 433 patients who stayed in the medical ICU for less than three days, mortality was greater among those receiving intensive insulin therapy.  Since the mean length of stay in our medical intensive care at the Phoenix VA was a little less than 3 days, many of our group became concerned that intensive control of glucose would not improve mortality and might actually prove harmful.

The GluControl study was undertaken in 2004 to test the hypothesis that intensive control of glucose (80-110 mg/dL) improves survival of patients treated in  medical/surgical intensive care units (ICU) compared to a control target of 140-180 mg/dL. Planned enrollment was 3500 subjects but the trial was stopped in 2006 after a little over 1000 subjects because interim analysis revealed numerous protocol violations resulting in hypoglycemia. The results were initially reported as an abstract at the 20th Congress of the European Society of Intensive Care in 2008 and a full length manuscript was published in 2009 (21,22). ICU, 28-day and hospital mortality were similar in both groups. ICU and hospital length of stay were identical. Hypoglycemia defined as a blood glucose below 40 mg/dL was seen in 8.7% of the intensive therapy group vs. 2.7% in the conventional group.

Further concern about the concept of intensive glucose control was raised by Weiner et al. (23) in 2008. They searched the medical literature (MEDLINE, the Cochrane Library, clinical trial registries, reference lists, and abstracts from conferences from both the American Thoracic Society and the Society of Critical Care Medicine) and identified 29 randomized controlled trials totaling 8432 patients.  A meta-analysis did not reveal a significant difference between intensive glucose control and usual care overall (21.6% vs. 23.3%) but did reveal an increased risk of hypoglycemia (glucose ≤40 mg/dL, 13.7% vs. 2.5%). In fact, the only study that showed a mortality advantage was van den Berge’s original study in 2001.

The NICE SUGAR Study

The landmark NICE SUGAR study (24) was published in the spring of 2009. This large study randomized 6104 patients to either intensive glucose control, with a target blood glucose range of 81 to 108 mg/dL, or conventional glucose control, with a target of <180 mg/dL. The main finding of the study was that intensive glucose control resulted in a 14% increase in morality. Furthermore, the adverse treatment effect on mortality did not differ significantly between surgical patients and medical patients. As in previous trials, severe hypoglycemia (blood glucose level ≤40 mg /dL) was significantly more common in the intensive-control group (6.8%) compared to the conventional-control group (0.5%, p<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU or hospital, the median number of days of mechanical ventilation or days of  renal-replacement therapy (p>0.05, all comparisons).

Follow up data was presented by Egi et al. (25) in patients admitted to 2 ICUs. The authors analyzed all those who had a blood glucose of <81 mg/dL to determine if there was an independent association between hypoglycemia and outcome. Of the 4946 patients admitted to the ICUs, 1109 had at least 1 episode of hypoglycemia. Mortality was higher in these patients (36.6%) compared with 19.7% in the nonhypoglycemic control patients (p<0.001). Mortality increased significantly with increasing severity of hypoglycemia (p<0.001). In fact, a minimum glucose of <36 mg/dL was associated with over a four-fold increase in ICU mortality compared to a minimum blood sugar of 72-81 mg/dL. After adjustment for insulin therapy, hypoglycemia was independently associated with increased risk of death, cardiovascular death, and death due to infectious disease.

Regulatory Agency Guidelines Following the NICE SUGAR Study

Following publication of the NICE SUGAR study most regulatory agencies dropped their recommendations for intensive glucose control in the ICU. However, remnants of the concept persist. IHI continues to promote “…effective glucose control in the intensive care unit (ICU) [which] has been shown to decrease morbidity across a large range of conditions and also to decrease mortality” (26). In another posting entitled “Establish a Glycemic Control Policy in Your ICU” (27) IHI states, “Typically, clinicians’ fear of inducing hypoglycemia is the first obstacle to overcome in launching an improvement effort. Doctors remain wary of inducing hypoglycemia and may not have confidence in selecting appropriate doses. Nurses fear hypoglycemia and remain concerned about protocolized adjustments to intravenous insulin rates of administration. The balance of evidence suggests, however, that once these barriers are addressed, ICU patients receive better care with appropriate glycemic control.”  Since hypoglycemia is associated with increased mortality in the ICU (22), this doctor and nurse fear of hypoglycemia seems well founded.

Hyperglycemia

Even though hypoglycemia is associated with excess mortality, hyperglycemia is also undesirable. As Falciglia et al. (28) point out, mortality increases with increasing admission glucose in the ICU. Although this is not the same as saying correcting the hyperglycemia improves mortality, it does suggest that hyperglycemia is undesirable. Furthermore, it has long been known that mortality is increased in patients with myocardial infarction and hyperglycemia (29). However, this increase in mortality with hyperglycemia does not apply to all disease states. For example, hyperglycemia in COPD or liver failure is not associated with increased mortality (28). This may have implications if the patients in a particular ICU population have predominately cardiac, respiratory or liver disease. However, even in this study an increase in mortality was noted with an admission blood sugar of <70 mg/dL to the ICU compared to a blood sugar of 70-100 mg/dL and approximates the mortality seen with an admission glucose of >300 mg/dL.

Conclusions and Recommendations

Based on the available evidence, we would suggest maintaining blood glucose levels of less than 180-200 mg/dL while avoiding blood sugars less than 80 mg/dL in the ICU. Intensive control of glucose is not evidence based, harmful, and should be discouraged. One might be somewhat more aggressive to maintain the blood sugar below 150 mg/dL in patients who are post-operative cardiac patients or receiving large infusions of glucose such as in van den Berge’s original study (13). However, avoidance of hypoglycemia is probably more important than maintaining a blood sugar below a certain level.

The rush to publish guidelines creating a standard of care of intensive regulatory control of glucose in the ICU seems irrational in retrospect and demonstrates a potentially continued threat to patient safety. In addition, these guidelines increased the workload of both nurses and clinicians. Although often thought to be revenue neutral, these mandates come at the price of increasing personnel costs both in implementation and monitoring of a guideline. Since personnel costs account for about 60-70% of the total costs in most health care systems, such mandates may be quite costly, or as the mandate for intensive glucose regulation illustrate, may actually be harmful. If the increase in mortality of 14% with intense glucose control is true as in the NICE SUGAR trial, this would calculate to one excess death for every 84 patients treated with this protocol (24,30). It seems unlikely that any ICU guidelines mandated in the future could compensate for the excess deaths caused by the mandated implementation of intense control of glucose. Fortunately, it is doubtful that implementation was 100%.

In an editorial entitled “Intensive insulin therapy in critical illness: when is the evidence enough?” Angus and Abraham (18) addressed the issue of when there is sufficient evidence for a concept to be widely applied as a guideline. Comparing the evaluation of intensive control of glucose in the ICU to evaluation of novel pharmacologic therapies, they point out that promising phase II studies are insufficient for regulatory approval. Instead, one, and usually two, large multicenter phase III trials are necessary to confirm reliability. The same principle is echoed in evidence-based medicine, where grade A recommendations are based on two or more large, positive, randomized, and multicenter trials. This seems a reasonable suggestion. Strong recommendations of this clinical importance should only be made when two or more large randomized controlled trials concur. However, it also seems unlikely that a mere review article such as this or the multiple recommendations from clinicians such as occurred with intensive control of glucose in the ICU will attenuate the exuberance of regulatory agents to mandate physicians and nurses to conform to their guidelines. Perhaps what is needed is an independent Federal or private agency to review and approve guidelines, and as Angus and Abraham suggest require at least two randomized, multicenter trials before implementation. As long as regulatory agencies accept no responsibility for harmful recommendations, it seems likely that in the absence of regulation, mistakes similar to the mandate to intensively regulate glucose in the ICU are likely to reoccur.

References

  1. University Group Diabetes Program: A study of the effects of 9. hypoglycemic agents on vascular complications in patients with adult-onset diabetes (parts I and II). Diabetes 1970;19:747-830.
  2. Kilo C. Value of glucose control in preventing complications of diabetes. Am J Med 1985;79:33-7.
  3. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. 
  5. Wolfe RR, Allsop JR, Burke JF. Glucose metabolism in man: responses to intravenous glucose infusion. Metabolism 1979;28:210-20.
  6. Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987;317:403-8.
  7. Shangraw RE, Jahoor F, Miyoshi H, et al. Differentiation between septic and postburn insulin resistance. Metabolism 1989;38:983-9.
  8. Malmberg K, Norhammar A, 8. Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.
  9. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997;314:1512-5.
  10. Malmberg K, Ryden L, Efendic S, et al. A randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects of mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
  11. Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-23.
  12. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD. A paradoxical gender dissociation within the growth hormone/ insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000;85:183-92.
  13. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
  14. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004;79:992-1000.
  15. Bellomo R, Egi M. Glycemic Control in the Intensive Care Unit: Why We Should Wait for NICE-SUGAR. Mayo Clin Proc 2005;80:1546-8.
  16. Malmberg K, Ryden L, Wedel H, et al., DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-661. 
  17. Mehta SR, Yusuf S, Diaz R, et al. CREATE-ELCA Trial Group Investigators. ST-segment elevation myocardial infarction: the REATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
  18. Angus DC, Abraham E. Intensive insulin therapy in critical illness: when is the evidence enough? Am J Resp Crit Care 2005;172:1358-9.
  19. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010;11:37.
  20. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. New Engl J Med 2006;354:449-61.
  21. Devos P, Preiser JC, Melot C. Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the Glucontrol study. Intensive Care Med 2007;33:S189 [abstract].
  22. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chioléro R. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-48.
  23. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933-44.
  24. NICE-SUGAR Study Investigators. Intensive versus conventional insulin therapy in critically ill patients. N Engl J Med 2009;360:1283-97.
  25. Egi M, Bellomo R, Stachowski E, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010;85:217-224.
  26. http://www.ihi.org/knowledge/Pages/Changes/ImplementEffectiveGlucoseControl.aspx (accessed 9-15-11)
  27. http://www.ihi.org/knowledge/Pages/Changes/EstablishaGlycemicControlPolicyinYourICU.aspx (accessed 9-9-11).
  28. Falciglia M,Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009;37:3001-9.
  29. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic review. Lancet 2000:355:773-8.
  30. Robbins RA. Changes in medicine: the decline of physician autonomy. Southwest J Pulm Crit Care 2011;3:49-51.
Monday
Aug222011

Analysis of Overall Level of Evidence Behind The Institute of Healthcare Improvement Ventilator-Associated Pneumonia Guidelines 

Reference as: Padrnos L, Bui T, Pattee JJ, Whitmore EJ, Iqbal M, Lee S, Singarajah CU, Robbins RA. Analysis of overall level of evidence behind the Institute of Healthcare Improvement ventilator-associated pneumonia guidelines. Southwest J Pulm Crit Care 2011;3:40-8. (Click here for PDF version of manuscript)

Leslie Padrnos1,4(lpadrnos@email.arizona.edu)

Tony Bui1,4 (tony.bui@cox.net)

Justin J. Pattee2,4 (backageyard@gmail.com)

Elsa J. Whitmore2,4 (elsa_whitmore@hotmail.com)

 Maaz Iqbal1,4 (maaziqbal@gmail.com)

Steven Lee3,4 (timmah2k@gmail.com)

Clement U. Singarajah2,4 (clement.singarajah@va.gov)

 Richard A. Robbins1,4,5 (rickrobbins@cox.net)

 

1University of Arizona College of Medicine

2Midwestern University-Arizona College of Osteopathic Medicine

3Kirksville College of Osteopathic Medicine

4Phoenix VA Medical Center

5Phoenix Pulmonary and Critical Care Research and Education Foundation

 

None of the authors report any significant conflicts of interest.

 

Abstract

Background 

Clinical practice guidelines are developed to assist in patient care but the evidence basis for many guidelines has recently been called into question.

Methods 

We conducted a literature review using PubMed and analyzed the overall quality of evidence and made strength of recommendation behind 6 Institute of Health Care (IHI) guidelines for prevention of ventilator associated pneumonia (VAP). Quality of evidence was assessed by the American Thoracic Society levels of evidence (levels I through III) with addition of level IV when evidence existed that the guideline increased VAP. We also examined our own intensive care units (ICUs) for evidence of a correlation between guideline compliance and the development of VAP.

Results 

None of the guidelines could be given more than a moderate recommendation. Only one of the guidelines (head of bed elevation) was graded at level II and could be given a moderate recommendation. One was graded at level IV (stress ulcer disease prophylaxis). The remainder were graded level III and given weak recommendations. In our ICUs compliance with the guidelines did not correlate with a reduction in VAP (p<0.05).

Conclusions 

Most of the IHI guidelines are based on level III evidence. Data from our ICUs did not support guideline compliance as a method of reducing VAP. Until more data from well-designed controlled clinical trials become available, physicians should remain cautious when using current IHI VAP guidelines to direct patient care decisions or as an assessment of the quality of care.

 

Introduction

The growth of guideline publications addressing nearly every aspect of patient care has been remarkable. Over the past 30 years numerous medical regulatory organizations have been founded to improve the quality of care. Many of these organizations have developed medical regulatory guidelines with 6870 listed in the National Guideline Clearinghouse (1). Many of these guidelines were rapidly adopted by healthcare organizations as a method to improve care.

Interest has grown in critically appraising not only individual clinical practice guidelines but also entire guideline sets of different medical (sub)specialties based on their rapid proliferation and in many instances an overall lack of efficacy in improving care (2,3). We assessed the quality of evidence underlying recommendations from one medical regulatory organization, the Institute for Healthcare Improvement (IHI), regarding one set of guidelines, the ventilator associated pneumonia (VAP) guidelines or VAP bundles (4). This was done by senior medical students during a month long rotation in the Phoenix Veterans Administration ICU. 

 

Methods

The study was approved by the Western Institutional Review Board.

Literature Search

In each instance PubMed was searched using VAP which was cross referenced with each component of the VAP bundle (as modified by the Veterans Administration) using the following MESH terms: 1. Elevation of the head of the bed; 2. Daily sedation vacation; 3. Daily readiness to wean or extubate; 4. Daily spontaneous breathing trial; 5. Peptic ulcer disease prophylaxis; and 6. Deep venous thrombosis prophylaxis. In addition, each individual component of the term was cross referenced with VAP. We also reviewed “Related citations” as listed on PubMed. Additional studies were identified using the “Related citations” in Pubmed from studies listed as supporting evidence on the IHI website and from the references of these studies.

Each study was assessed for appropriateness to the guideline. Studies were required to be prospective and controlled in design. Only studies demonstrating a reduction in VAP were considered, i.e., surrogate outcomes such as reduction in duration of mechanical ventilation were not considered. 

The American Thoracic Society grading system was used to assess the underlying quality of evidence for the IHI VAP guidelines (5) (Table 1). Only evidence supporting a reduction in VAP was considered. We added category IV when there was literature evidence of potentially increasing VAP with the use of the recommendation. A consensus was reached in each case. 

Table I. Levels of Evidence

Level of Evidence

Definition

Level I (high)

 

Evidence from well-conducted, randomized controlled trials.

 

Level II (moderate)

 

Evidence from well-designed, controlled trials without randomization (including cohort, patient series, and case-control

Studies). Level II studies also include any large case series in which systematic analysis of disease patterns was conducted, as well as reports of data on new therapies that were not collected in a randomized fashion.

Level III (low)

 

Evidence from case studies and expert opinion. In some instances, therapy recommendations come from antibiotic susceptibility data without clinical observations.

Level IV

No evidence of improvement with some evidence of an increase in a negative outcome.

 

Guideline Compliance and VAP Incidence

We also assessed our ICUs for additional evidence of the effectiveness of the VAP bundle. Data was collected for a period of 50 months from January, 2007 through February, 2011. This was after the Veterans Administration requirements for VAP reporting and IHI compliance was instituted. Diagnosis and compliance were assessed by a single quality assurance nurse using a standardized protocol (6). Statistical analysis was done using a Pearson correlation coefficient with a two-tailed test. Significance was defined as p<0.05.

 

Results

Literature Review

Numbers of articles identified by PubMed search and used for grading the level of evidence and strength of recommendation are given in Table 2. Also included are the level of evidence and the strength of the recommendation.

Table 2.

 

Guideline

Total Articles

No. of Articles Used (references)

Level of Evidence

Strength of Recommendation

 

Elevation of the head of the bed

31

8 (7-14)

II

Moderate

Daily sedation vacation

66

4 (15-18)

III

Weak

Daily readiness to wean or extubate

47

3 (19-21)

III

Weak

Daily spontaneous breathing trial

29

1 (22)

III

Weak

Peptic ulcer disease prophylaxis

52

9 (23-29)

IV

Weak

Deep venous thrombosis prophylaxis.

14

2 (30-31)

III

Weak

Head of Bed Elevation

A literature search identified 31 articles of which 8 were used in evaluating this guideline (7-14). However, only 2 specifically studied head of bed elevation with one supporting and another not supporting the intervention (7,8). Consequently it was graded as level II and the strength of recommendation was graded as moderate.

Daily Spontaneous Breathing Trial, Daily Readiness to Wean, and Daily Sedation Vacation

From 1-4 studies were identified for each of these interventions, however, none demonstrated a reduction in VAP. Consequently, it was judged that the evidence basis was level III and the strength of recommendation was graded as weak.

Stress Ulcer Disease Prophylaxis

We found no evidence that stress ulcer disease prophylaxis decreased VAP (23-29). There was some evidence that acid suppressive therapy increased pneumonia and VAP. Consequently, it was judged to be a level IV (possibly increasing VAP). 

Deep Venous Thrombosis Prophylaxis

We could find no evidence that deep venous thrombosis prophylaxis decreased VAP (30,31).

Guideline Compliance and VAP Incidence

Beginning in the first quarter of fiscal year 2007 there was a significant decrease in the incidence of VAP in our hospital (33). This coincided with the requirement for the monitoring of VAP, compliance with the VAP bundles and our adoption of endotracheal aspiration with nonquantitative culture of the aspirate as opposed to bronchoalveolar lavage which had been out standard practice. We changed practices because bronchoalveolar lavage with quantitative cultures appeared to offer no improvement in clinical outcomes to endotracheal aspiration (34). In our medical and surgical ICUs, 5097 audits representing 5800 ventilator-days were assessed. Nineteen cases of VAP were identified with an average of 2.1 VAP infections/1000 ventilator-days.  We assessed our surgical and medical ICUs, combined and separately, for a correlation between total bundle compliance and each component of the VAP bundle with VAP incidence (Appendices 1-3). There was no significant correlation between compliance with the bundles and VAP (p<0.05).

 

Discussion

This manuscript questions the validity of the VAP bundles as proposed by the IHI. We found that a systematic review of the literature revealed predominately weak evidence to support these guidelines. Only one guideline (head of bed elevation) was supported by a randomized trial (7), but an additional, larger trial showed no decrease in VAP (8). Furthermore, data from our own ICUs showed no evidence of IHI VAP guideline compliance with a reduction in VAP.

Head of bed elevation is a relatively simple and easy to perform intervention which may reduce VAP. Studies examining aspiration have shown a reduction in critical care patients with the head of bed elevation but it is unclear whether this translates into a reduction in VAP (36,37). Drakulovic et al. (7) reported a randomized controlled trial in 86 mechanically ventilated patients assigned to semi-recumbent or supine body position.  The trial demonstrated that suspected cases of ventilator-associated pneumonia had an incidence of 34 percent while in the semi-recumbent position suspected cases had an incidence of 8 percent (p=0.003).  However, another study in 221 subjects demonstrated that the target head elevation of 45 degrees was not achieved for 85% of the study time, and these patients more frequently changed position than supine-positioned patients (8). The achieved difference in treatment position (28 degrees vs. 10 degrees) did not prevent the development of ventilator-associated pneumonia. The other 5 articles identified either did not identify head of bed elevation directly or as part of a bundle. Most were a before and after design and not randomized. Therefore, it is difficult to draw any meaningful conclusions.

The IHI groups daily "sedation vacations" and assessing the patient’s “readiness to extubate.” The logic is that more rapid extubation leads to a reduction in VAP. Kress et al. (15) conducted a randomized controlled trial in 128 adult patients on mechanical ventilation, randomized to either daily interruption of sedation irrespective of clinical state or interruption at the clinician’s discretion. Daily interruption resulted in a reduction in the duration of mechanical ventilation from 7.3 days to 4.9 days (p=0.004). However, in a retrospective review of the data, the authors were unable to show a significant reduction in VAP (16).

Stress ulcer prophylaxis and deep venous thrombosis prophylaxis are routine in most ICUs. However, stress ulcer prophylaxis with enteral feeding is probably as effective as acid suppressive therapy and acid suppressive therapy may increase the incidence of VAP (38). Deep venous thrombosis prophylaxis has been shown to decrease the incidence of pulmonary emboli but not improve mortality (32). Although we use these interventions in our ICU, we would suggest that these would be more appropriate for recommendations rather than guidelines.

The diagnosis of VAP is difficult, requiring clinical judgment even in the presence of objective clinical criteria (6). The difficulty in diagnosis, along with the negative consequences for failure to follow the IHI guidelines, makes before and after comparisons of the incidence of VAP unreliable. Therefore, we sought evidence for the effectiveness of VAP prevention guidelines reasoning that the better the compliance with the guidelines, the lower the incidence of VAP. We were unable to show that improved VAP guideline compliance correlated with a reduced incidence of VAP.

The IHI guidelines would not meet the criteria outlined earlier in an editorial in the Southwest Journal of Pulmonary and Critical Care for a good guideline:

Our study has several limitations. No literature review is totally comprehensive. It is possible that studies relevant to the IHI VAP guidelines, especially those written in a foreign language, were not identified. Second, the Phoenix VA data may be underpowered to show a small beneficial effect despite having over 5000 patient audits. Third, as with other healthcare facilities, the VAP guidelines at our institution were mandated and monitored. The threat of negative consequences may have compromised the objective assessment of the data, likely invalidating a before and after comparison. Fourth, correlation between guideline compliance and VAP incidence is not a substitute for a randomized trial. Unfortunately, the later is not possible given that guideline compliance is mandated.

It is unclear why the IHI guidelines have received such wide acceptance given their weak evidence basis. Agencies involved in guideline writing should show restraint in guideline formulation based on opinion or weak or conflicting evidence. Only those interventions based on strong evidence which can make a real difference to patients should be designated as guidelines.

 

Acknowledgements

The authors acknowledge Janice Allen, MSN, RN who collected the VAP data reported from the Phoenix VA.

References

  1. http://www.guideline.gov/ Accessed 3-16-2011.
  2. Lee DH, Vielemeyer O. Analysis of overall level of evidence behind infectious diseases society of America practice guidelines. Arch Intern Med 2011;171:18-22.
  3. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, For KD, Scerpella EG, Ramirez JA. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study.  Lancet Infect Dis 2011 Jan 19. [Epub ahead of print].
  4. http://www.ihi.org/IHI/Topics/CriticalCare/IntensiveCare/Changes/ImplementtheVentilatorBundle.htm. Accessed 3-16-2011.
  5. Schünemann H, Jaeschke R, Cook DJ, et al. An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and Recommendations. Am J Resp Crit Care Med 2006;174:605-14.
  6. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
  7. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet 1999;354:1851-8.
  8. van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, Joore HC, van Schijndel RJ, van der Tweel I, Ramsay G, Bonten MJ. Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. Crit Care Med 2006;34:396-402.
  9. Baxter AD, Allan J, Bedard J, Malone-Tucker S, Slivar S, Langill M, Perreault M, Jansen O. Adherence to simple and effective measures reduces the incidence of ventilator-associated pneumonia. Can J Anaesth 2005;52:535-41.
  10. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care 2008;23:126-37.
  11. Wip C, Napolitano L. Bundles to prevent ventilator-associated pneumonia: how valuable are they? Curr Opin Infect Dis. 2009;22:159-66.
  12. Laux L, Dysert K, Kiely S, Weimerskirch J. Trauma VAP SWAT team: a rapid response to infection prevention. Crit Care Nurs Q 2010;33:126-31.
  13. Bird D, Zambuto A, O'Donnell C, Silva J, Korn C, Burke R, Burke P, Agarwal S. Adherence to ventilator-associated pneumonia bundle and incidence of ventilator-associated pneumonia in the surgical intensive care unit.  Arch Surg 2010;145:465-70.
  14. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, Lomeña F, Rodríguez-Roisin R. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992;116:540-3.
  15. Kress JP, Pohlman, AS, O'Connor, MF, Hall,JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471-1477.
  16. Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB,  Kress JP. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med 2004; 32:1272–6.
  17. Mehta, S. A randomized trial of daily awakening in critically ill patients managed with a sedation protocol: a pilot trial. Critical Care Medicine 2008; 36:2092-9.
  18. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled Trial): A randomized contolled trial.  Lancet 2008;371:126-34.
  19. Marelich GP, Murin S, Battistella F, Inciardi J, Vierra T, Roby M. Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: Effect on weaning time and incidence of ventilator-associated pneumonia. Chest 2000;118:459-67.
  20. Jain M, Miller L, Belt D, King D, Berwick DM.  Decline in ICU adverse events, nosocomial infections and cost through a quality improvement initiative focusing on teamwork and culture change.  Qual Saf Health Care 2006; 15: 235–239.
  21. Resar RK. Making noncatastrophic health care processes reliable: learning to walk before running in creating high-reliability organizations. Health Serv Res 2006; 41: 1677–89.
  22. Liang JF, Tian R, Feng L. Clinical experience of spontaneous breathing trial in weaning mechanical ventilation.  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21:617-20.
  23. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care 2002;17:240-5.
  24. Lopriore E, Markhorst DG,  Gemke RJ. Ventilator-associated pneumonia and upper airway colonization with Gram negative bacilli: the role of stress ulcer prophylaxis in : the role of stress ulcer prophylaxis in children. Intensive Care Med 2002;28:763–767.
  25. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
  26. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
  27. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
  28. Cook DJ, Laine LA, Guyatt GH, Raffin TA. Nosocomial pneumonia and the role of gastric pH: A meta-analysis. Chest 1991;100:7-13.
  29. Chua LC, Mehta M, MD, Bhutani S, Schorr C, Milcarek B, Gerber D.  Early ventilator-associated pneumonia in patients on outpatient acid-suppressive therapy.  Chest  2010;138:730A [Abstract].
  30. Wahl WL, Talsma A, Dawson C, Dickinson S, Pennington K, Wilson D, Arbabi S, Taheri PA. Use of computerized ICU documentation to capture ICU core measures Surgery 2006; 140:684-9.
  31. Pronovost PJ, Berenholtz SM, Ngo K, McDowell M, Holzmueller C, Haraden C, Resar R, Rainey T, Nolan T, Dorman T. Developing & pilot testing quality indicators in the intensive care unit. Journal of Critical Care 2003;18:145-55.
  32. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278-88.
  33. Benneyan JC, Lloyd RC, Plsek PE. Statistical process control as a tool for research and healthcare improvement. Qual Safe Health Care 2003 ;12:458-64.
  34. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619-30.
  35. Robbins RA, Thomas AT Raschke RA. Guidelines, recommendations and improvement in healthcare. Southwest J Pulm Crit Care 2011;2;34-37.
  36. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, Lomeña F, Rodríguez-Roisin R. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992;116:540-3.
  37. Orozco-Levi M, Torres A, Ferrer M, Piera C, el-Ebiary M, de la Bellacasa JP, Rodriguez-Roisin R. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 1995;152:1387-90.
  38. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: A systematic review and meta-analysis. Critical Care Medicine 2010:38;2222-8.

Appendices

Click here for Appendix 1. VAP rate in all ICUs

Click here for Appendix 2. VAP in medical ICU

Click here for Appendix 3. VAP in surgical ICU

Saturday
Jun182011

ARTERIAL AMMONIA LEVELS IN THE MANAGEMENT OF FULMINANT LIVER FAILURE

Robert Raschke

Steven Curry

Silke Remke

Ester Little

Richard Gerkin

Richard Manch

Alan Leibowitz

Banner Good Samaritan Regional Medical Center, Phoenix, AZ

Reference as:  Raschke R, Curry S, Remke S, Little E, Gerkin R, Manch R, Leibowitz A. Arterial ammonia levels in the management of fulminant liver failure. Southwest J Pulm Crit Care 2011;2:85-92. (Click here for PDF version)

Abstract

Previous studies have suggested that an arterial ammonia level greater than 150 mmol/L is highly sensitive for predicting subsequent development of cerebral edema in patients with fulminant liver failure. We performed a prospective cohort study to confirm this relationship. We enrolled 22 consecutive patients who presented to our transplant hepatology service with grade 3-4 encephalopathy associated with fulminant liver failure. All patients underwent placement of an intraparenchymal ICP monitor, and every 12 hourly arterial ammonia levels. The prevalence of intracranial hypertension (IHTN) in our population was 95% (21/22 patients), with 82 discrete episodes recorded. The sensitivity of arterial ammonia levels to predict the onset of IHTN was 62% (95% CI: 40.8 to 79.3) at a cut point of 150 mmol/L. Arterial ammonia levels preceding the first intracranial hypertension event were less than 150 mmol/L in 8 of 21 patients (39%). Fifty nine of 82 episodes of IHTN (73%) occurred when arterial ammonia levels were less than 150 mmol/L. We conclude that the arterial ammonia level is not useful in making decisions regarding management related to cerebral edema in patients with fulminant liver failure. In fact, since almost all our study patients with grade III or IV encephalopathy secondary to fulminant liver failure went on to develop intracranial hypertension, our study supports the contention that all such patients might benefit from ICP monitoring regardless of arterial ammonia levels.

Background

Cerebral edema is the most common cause of death in fulminant liver failure (FLF) (1,2), occurring in 80% of patients with advanced encephalopathy (3). Cerebral edema causes brain injury by compromising cerebral perfusion pressure and/or by causing cerebral herniation. Intracranial hypertension (IHTN) is the most reliable sign of cerebral edema, and is defined as an intracranial pressure (ICP) greater than 20 mmHg (4-6). Many authors have recommended ICP monitoring in FLF to guide management of cerebral edema (7,8) although this procedure entails significant hemorrhagic risk (9,10).

The pathogenesis of cerebral edema in FLF is likely multifactorial, but substantial evidence supports a causal role for hyperammonemia. Elevated ammonia levels alter neurotransmitter synthesis, and interfere with mitochondrial function causing oxidative stress and neuronal apoptosis (4,5,6,11-16). Increased delivery of ammonia to astrocytes provides substrate for the accumulation of intracellular glutamine (17-18). The resulting osmotic effect causes astrocyte swelling and cerebral edema (6,7,19). Clinical studies have repeatedly shown that arterial ammonia levels around 150 mmol/L have a statistically significant association with the development of IHTN and cerebral edema in humans (8,20-22).

Clemmensen and colleagues (8) measured arterial ammonia levels at the onset of grade III encephalopathy in 44 patients with FLF. Fourteen of those patients subsequently developed cerebral herniation. The patients who developed cerebral herniation had significantly higher mean arterial ammonia levels (230 vs. 118 μmol/L P<0.001), and all had ammonia levels > 146 μmol/L. At this cut point, arterial ammonia had a sensitivity of 100%, a specificity of 73% and a PPV of 64% for the subsequent development of cerebral herniation (8).

The results of this study raised the possibility that arterial ammonia levels could be used to select FLF patients likely to benefit from ICP monitoring. If arterial ammonia levels above 146 μmol/L were highly sensitive for predicting the development of IHTN, patients with arterial ammonia levels below this threshold would not likely benefit from ICP monitoring, therefore the significant hemorrhagic risk of monitor placement could be avoided (20,23).

The primary aim of our study was to confirm this premise by reassessing the sensitivity of the arterial ammonia concentration for predicting the onset of intracranial hypertension (IHTN). We chose IHTN as our dependent variable since cerebral herniation is uncommonly seen in patients managed with our neuroprotective treatment protocol (24), and because intracranial hypertension can cause brain injury by compromising cerebral perfusion in the absence of herniation. The secondary aim of our study was to determine whether following serial arterial ammonia levels are valuable in predicting the timing of recurrent IHTN episodes before and after liver transplantation.

Methods

A prospective case series was approved by the Institutional Review Board at Banner Good Samaritan Regional Medical Center, a 650 bed community teaching hospital in Phoenix Arizona. The Transplant Hepatology service identified consecutive patients admitted with FLF, as defined by standard criteria (20) between May 2004 and September 2006. All patients underwent serial neurological examinations by an intensivist, and those who developed grade 3-4 encephalopathy were evaluated for study participation. Eligible patients’ families were asked to provide informed consent.

Serial arterial ammonia levels were obtained in study patients. An arterial catheter was placed and 5 cc of arterial blood was drawn into a sodium heparin-containing tube every 12 hours. These samples were transported to the chemistry laboratory on ice within 30 minutes. Quantitative plasma ammonia concentrations were performed using an enzymatic kinetic assay (Roche Diagnostics, Mannheim Germany). This assay has a reportable range of 5.87-587 mmol/L and a coefficient of variability of 2%.

An intraparenchymal ICP monitor (Codman MicroSensor® - Codman/Johnson & Johnson Professional, Inc., Randolph, MA) was placed in the non-dominant frontal lobe under local anesthesia by a neurosurgeon. The ICP was monitored continuously thereafter. Hemostatic therapy and ICP management used in the study have been previously described (24). ICP monitors were removed post-transplantation when the patient could tolerate lowering of their head to zero degrees without precipitating IHTN. In patients who did not undergo transplantation, ICP monitors were removed upon clinical recovery or death.  

Our main independent variable was the arterial plasma ammonia level. Our main dependent variable was intracranial hypertension, defined as an ICP > 20 mmHg for > 20 mins.  We performed 3 separate sets of analyses to examine the relationship between arterial ammonia levels and IHTN: 1) we analyzed the arterial ammonia level that most closely preceded the onset of the first episode of IHTN in each patient; 2) we analyzed all arterial ammonia levels in relation to all episodes of IHTN; and 3) we analyzed all arterial ammonia levels in relation to all episodes of IHTN occurring post liver transplantation. The second and third analyses involved data values that were not independent of each other, therefore standard statistical techniques were not appropriate and time series analysis was performed. Statistical analyses were performed using SPSS 13.0 (SPSS Inc. Chicago IL.) Operating characteristics of arterial ammonia levels were calculated at a cut point of 150 mmol/L.  

Results

Twenty two patients were entered – their clinical characteristics at study entry are listed in Table 1.

Table 1:  Patient Characteristics:

Mean age:

32.7 years (S.D. 10.3 yrs, range 15-56)

Gender:

17/22 (77%) female

Etiology:

acetaminophen toxicity (12 patients)

hepatitis A (3)

hepatitis B (1)

anticonvulsant hypersensitivity syndrome (1)

sulfa hypersensitivity syndrome (1)

Wilson’s disease (1)

Cryptogenic (3)

Encephalopathy grade:

8 patients (36%) Grade III

14 patients (64%) Grade IV

 

Our 22 patients cumulatively underwent 3252 hours of ICP monitoring. Mean monitor duration was 147.8 +/- 143.3 hours. Monitors were left after liver transplantation in nine patients for 85.6 +/- 60.6 hours.

The prevalence of IHTN in our population was 95% (21/22 patients). Eighty-two discrete episodes of intracranial hypertension occurred. 62 occurred prior to, 4 during, and 16 after liver transplantation. The peak ICP during IHTN events was 33 +/- 13 mmHg (mean +/- S.D.) and the median duration was 60 minutes.

Relationship between arterial ammonia levels and the first episode of IHTN: The mean arterial ammonia level preceding the first intracranial hypertension event in each patient was 185 +/- 67 mmol/L (range: 96 – 337 mmol/L). The sensitivity of arterial ammonia levels to predict the onset of IHTN was 62% (95% CI: 40.8 to 79.3) at a cut point of 150 mmol/L. Arterial ammonia levels preceding the first intracranial hypertension event were less than 150 mmol/L in 8 of 21 patients (39%). We could not accurately calculate specificity or area under the receiver operator curve (AUROC) since only one patient did not develop IHTN.  

Relationship between arterial ammonia levels and all episodes of IHTN: The mean arterial ammonia levels just prior to each of the individual 82 episodes of IHTN were 122 +/- 80 mmol/L (range: 15 – 270 mmol/L). Fifty nine of 82 episodes of IHTN (73%) occurred when arterial ammonia levels were less than 150 mmol/L.

Relationship between arterial ammonia levels and all episodes of IHTN occurring post liver transplantation: Nine patients underwent liver transplantation. Seventy-nine ammonia levels were obtained post-liver transplantation in these patients. Four transplant recipients experienced 16 post-operative IHTN events. The mean arterial ammonia just prior to each of these events was 70 +/- 48 mmol/L (range: 15 – 161 mmol/L). The sensitivity of the arterial ammonia level preceding each IHTN event was 13% and the specificity was 100% at a cut point of 150 mmol/L. Arterial ammonia levels were statistically lower in post-transplant IHTN episodes than in pre-transplant episodes (P<0.001).

Discussion

Our study showed that almost all patients with grade III or IV encephalopathy secondary to fulminant liver failure will develop intracranial hypertension – this supports the possible benefit of intracranial pressure monitoring in all such patients regardless of arterial ammonia levels. Although the high prevalence of IHTN in our study population prevented us from calculating the specificity of arterial ammonia levels, sensitivity is the key characteristic of this test in terms of our research question. Our study shows that arterial ammonia levels > 150 mmol/L are not sensitive for subsequent development of IHTN, and therefore should not be used to identify a subset of patients unlikely to benefit from ICP monitoring.

Our study did not confirm the clinical utility of arterial ammonia levels in predicting neurological injury in patients with FLF, as suggested by Clemmensen et al (8). This could be because the clinical event of interest in the two studies differed – Clemmensen focused on cerebral herniation, and we measured IHTN directly. Cerebral herniation occurred in 14 of Clemmensens’ 44 patients, but it was not observed in our patients. Our study utilized a management protocol specifically designed to prevent cerebral herniation (24). It is unknown how many of our patients with IHTN would have gone on to herniate if IHTN had not been detected and aggressively treated.           

Several other studies have examined the predictive value of arterial ammonia levels for cerebral edema and IHTN in patients with acute liver failure. Bernal and colleagues studied 165 patients with acute liver failure and grade 3-4 encephalopathy and found that arterial ammonia on admission was higher in those who later developed IHTN (121 vs 109 mmol/L p<0.05 (20). However, the sensitivity of an ammonia cut-point of 150 mmol/L was only 40%, and the positive predictive value (probability that a patient with ammonia > 150 mmol/L would develop IHTN) was only 16%.   

Bhatia and colleagues studied 80 patients with ALF, 58 of whom had grade 3-4 encephalopathy (21). They calculated an optimal cut-point for arterial ammonia for predicting mortality was 124 mmol/L by ROC analysis. Patients with ammonia levels above this cutpoint had a higher frequency of cerebral edema (47% vs. 22% P=0.02). Sensitivity and positive predictive values can be calculated from data presented in their paper, and are 71% and 48% respectively.  

Our results confirm those of Bernal and Bhatia in that all 3 studies showed that the operating characteristics of the arterial ammonia test are insufficient for triaging ALF patients in regards to invasive ICP monitoring. But our study has several important differences. IHTN or cerebral edema was detected in only 29% of Bernal’s patients and 35% of Bhatia’s. Both studies relied heavily on physical examination to diagnose these outcomes despite evidence that it lacks the sensitivity to do so (1,3,25-27). Our study utilized the gold standard (ICP monitoring) in all our patients. We found a much higher prevalence of IHTN – 95% in patients with grade 3-4 encephalopathy. This high prevalence explains the higher positive predictive value in our study, and suggests that previous studies may have suffered from significant underdetection of IHTN and cerebral edema.

Our study is also unique in that we performed repeated measures of arterial ammonia. This was important in terms of our hypothesis that patients’ risk for IHTN might change over time in response to treatments such as lactulose, continuous renal replacement therapy, and liver transplantation. Unfortunately, we found that repeated measures of arterial ammonia were no more clinically useful than the single levels used in previous studies.

Our study has several important limitations. Our limited sample size produced wide confidence intervals about our estimation of sensitivity. Our study only included patients with advanced encephalopathy - it’s possible that arterial ammonia levels might demonstrate improved prognostic significance earlier in the course of FLF. We did not attempt to analyze the effect of cumulative ammonia exposure over time.

 Our findings, and those of previous investigators, suggest that other factors besides peak ammonia levels are important in the pathogenesis of FLF-induced cerebral edema. Two other proposed causative factors are pathological alterations in cerebral blood flow (28-32) and systemic inflammatory response (30,33-34). The interplay of all three factors may be critical to the pathogenesis of cerebral edema in FLF and this might explain why simple measurement of serum ammonia is not sufficient to predict IHTN.

   Further work is needed to elucidate the pathogenesis of IHTN in FLF and identify variables that predict which patients will develop this life-threatening complication. Until then, we suggest that all patients with grade 3 or 4 encephalopathy secondary to FLF are at high risk. Our study shows that arterial ammonia levels in these patients cannot be relied upon to accurately triage patients in regards to their risk for IHTN. Thus, it is not helpful in determining which patients might benefit from ICP monitoring, nor determining when ICP monitoring can safely be discontinued.

Conclusions

An arterial ammonia level of 150 mmol/L is poorly sensitive for determining which patients with ALF will develop IHTN and should not be used to determine which patients are likely to benefit from ICP monitoring. The prevalence of IHTN in FLF patients with grade 3-4 encephalopathy is so high that no other predictive test is likely to be of added value. Although arterial ammonia levels are correlated with episodes of IHTN, most individual IHTN episodes occur when arterial ammonia levels are < 150 mmol/L. After successful transplantation IHTN events can continue to occur even as ammonia levels enter the normal range.

References

1. Lee WM. Management of acute liver failure. Semin Liver Dis 1996; 16:369-378.

2. Ellis AJ, Wendon J. Circulatory, respiratory, cerebral and renal derangement in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16: 379-389.

3. Gill R., Sterling R, Acute Liver Failure. Journal of Clinical Gastroenterology 2001; 33 (3.:191-198.

4.Blei AT, Brain edema and portal-systemic encephalopathy. Liver Transplantation. 2000;6(Suppl 1.:S14-S20.

5. Kato M, Hughes RD, Keays RT, Williams R. Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure. Hepatology. 1992;15:1060-66.

6. Blei AT, Olafsson S, Therrien G, Butterworth RF. Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology. 1994;19:1437-44.

7. Takahashi H, Koehler RC, Brusilow SW, Traystman RJ. Inhibition of brain glutamine accumulation prevetns cerebral edema in hyperammonemic rats. Am J Physiol. 1991;261:H825-H829.

8. Clemmessen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patient with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648-653.

9. Lee WM. Acute liver failure. N England J Med 1993; 329: 1862.

10. Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet. 1993;341: 157-8.

11. Vaquero J, Chung C, Blei AT. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Annals of Hepatology. 2003;2:12-22.

12. Tofteng F, Jorgensen L, Hansen BA, Ott P, Koadrap J, Larsen FS. Cerebral microdialysis in patients with fulminant hepatic failure. Hepatology. 2002;36:1333-40.

13. Kosenko E, Felipo V, Montolia C, Grisolia S, Kaminsky Y. Effectos of acute hyperammonemia in vivo on oxidative metabolism in nonsynaptic rat brain mitochondria. Metabolic Brain Diseases. 1996;12:69-82.

14. Norenberg MD. Oxidative and nitrosative stress in ammonia neurotoxicity. Hepatology. 2003;37:245-8.

15. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Seminars in liver disease. 2003;23:259-69.

16. Widmer R, Kaiser B, Engels M, Jung T, Grune T. Hyperammonemia causes protein oxidation and enhanced proteasomal activity in response to mitochondria-mediated oxidative stress in rat primary astrocytes. Arch Biochem Biophys. 2007;464:1-11.

17. Swain M, Butterworth RF, Blei AT. Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats. Hepatology. 1992;15:449-53.

18. Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic osmolytes after portocaval anastomosis in the rat: Implications for ammonia-induced brain edema. Hepatology. 1996;24:919-23.

19. Tofteng F, Hauerberg J, Hansen BA, Pedersen CB, Jorgensin L, Larsen FS. Persistant arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. J Cereb Bood Flow Metab. 2006;26:21-7..

20. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46:1844-52.

21. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut. 2006;55:98-104.

22. Kundra A, Jain A, Banga A, Bajaj G, Kar P. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem. 2005;38:696-9.

23. Bass NM. Monitoring and treatment of intracranial hypertension. Liver Transplantation 2000; 6(4. Supp1:S21-S26

23. Davern TJ. Predicting prognosis in acute liver failure: Ammonia and the risk of cerebral edema. Hepatology. 2007;46:1679-81.

24. Raschke RA, Curry SC, Rempe S, Gerkin R, Little E, Manch R, Wong M, Ramos A, Leibowitz AI. Results of a Protocol for the Management of Patients with Fulminant Liver Failure. Critical Care Medicine. 2008;36:2244-8.

25. Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: Summary of a workshop. Hepatology. 1995;21:240-52.

26. Canalese J, Gimson AES, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982;23:625-9.

27. Brajtbord D, Parks RI, Ramsay MA, Paulsen AW, Valek TR, Swygert TH, Klintmalm GB. Management of acute elevation of intracranial pressure during hepatic transplantation. Anesthesiology. 1989;70:139-141.

28. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology. 1994;19:1407-13.

29. Sari A, Yamashita S, Ohosita S, Ogasahara H, Yamada K, Yonei A, Yokota K. Cerebrovascular reactivity to CO2 in patients with hepatic or septic encephalopathy. Resuscitation. 1990;19:125-34

30. Jalan r, Olde Damink SWM, Hayes PC, Deutz NEP, Lee A. Pathogenesis of intracranial hypertension in acute liver failure: Inflammation, ammonia and cerebral blood flow. Journal of Hepatology. 2004;41:613-20.

31. Kramer D, Aggarwal M, Darby J, Obrist W, Rosenbloom A, Murray G, Linden P, et al. Management options in fulminant hepatic failure. Transplant Proc. 1991;23:1895-8.

32. Jalan R, Olde Damink SWM, Deutz NEP, Hayes PC, Lee A. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology. 2001;34:50-4.

33. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32:734-9

34. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, Lee W, Blei AT, and the U.S. Acute Liver Failure Study Group. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology.2003;125:755-64.     

Tuesday
Jun142011

RIGHT PLEURAL INSERTION OF A SMALL BORE FEEDING TUBE

Clement U. Singarajah

 Tyler Glenn

Richard A. Robbins

Phoenix VA Medical Center, Phoenix, AZ

Reference as: Singarajah CU, Glenn T, Robbins RA. Right pleural insertion of a small bore feeding tube. Southwest J Pulm Crit Care 2011;2:71-6. (Click here for PDF version)

Abstract

We report a case of a 56 year old man who had a feeding tube inadvertently malpositioned into the right pleural space and had approximately 600 ml of tube feedings infused. After the malposition was recognized, the patient underwent chest tube placement, followed by video assisted thoracic surgery 5 days later. He made an uneventful recovery. The case illustrates the problems with identification and treating feeding tube insertion into the lung.  

Case Presentation

History of Present Illness

A 56 year old male was transferred from another hospital where he had been admitted 9 days earlier for severe community acquired pneumonia secondary to penicillin sensitive Streptococcus pneumoniae, respiratory failure and sepsis syndrome. He had a past medical history of morbid obesity, type 2 diabetes mellitus, hepatitis C, hypertension and had received a pneumococcal vaccination 8 years earlier. His course was complicated by prolonged mechanical ventilation, hypotension resulting in oliguric acute renal failure and atrial fibrillation with a fast ventricular response requiring cardioversion. He had sufficiently improved with antibiotics, hemodialysis and supportive therapy that he was able to be transferred to our hospital. He had a prolonged but uncomplicated course in our intensive care unit (ICU). He was initially unable to be weaned from mechanical ventilation and underwent tracheostomy but was eventually able to tolerate tracheostomy collar and intermittent use of a tracheostomy tube with a speaking valve. He was noted to be intermittently confused and agitated. After 17 days in our ICU, transfer was planned to a general medical floor.  However, prior to leaving our ICU he pulled his feeding tube and another small bore feeding tube was inserted. An abdominal film was performed and he was transferred to the medical floor. After transfer he complained through the night of chest pain and shortness of breath and required increasing inspired oxygen concentrations in order to maintain adequate oxygen saturation. .

Physical Examination

Physical examination was not markedly changed from the previous day. He had a tachycardia of 110, blood pressure of 139/97, respirations of 24, temperature of 36.3 degrees C and weight of 140.6 kilograms. He was not oriented to time or place and seemed to be in moderate discomfort. Pertinent findings including a small bore feeding tube in his left nostril, a tracheotomy in place and rhonchi over both lungs. Abdomen was protuberant but soft and there was no presacral or pretibial edema.

Laboratory Findings

Pertinent laboratory findings included arterial blood gases showing a pH of 7.44, pCO2 of 32 mm Hg, and pO2 of 65.3 on a FiO2 of 0.7. Blood glucose was elevated at 275 and his white blood cell count had increased from 6000/microL on the day of transfer to the floor to 11,400/microL with a left shift.

Radiography

Initial abdominal films are show in figure 1.

Figure 1. Panel A and B are abdominal x-rays taken for feeding tube placement. Panel A shows the feeding tube below the diaphragm indicated by the arrow. Panel B, labeled at the same time and with the same acquisition number does not show the tube below the diaphragm but shows a tube apparently in the right chest. Panel C is an inverted image of Panel B.

A chest X-ray was taken on the patient’s return to the intensive care unit (Figure 2).

 

Figure 2. A. Chest X-ray shows feeding tube in trachea and right mainstem bronchus, looping in lower right chest and extending to upper right chest (arrows). B. Inverted image of A.

Hospital Course

Because of his high oxygen requirements and dyspnea, the patient was placed on mechanical ventilation. Bronchoscopy confirmed that the tube was in the lung. Due to concern for a pneumothorax should the tube be removed, a chest tube was placed first and directed to drain the pleural effusion. The feeding tube was removed and a follow up chest x-ray confirmed a pneumothorax that was treated with another chest tube. It was estimated that about 600 ml of feeding formula had been infused into the chest. Approximately 700 ml of milky fluid consistent with feeding was collected by the thoracostomy tube. Thoracic surgery consultation was obtained and recommended video-assisted thoracic surgery which was performed 5 days latter. A small amount of what appeared to be feeding formula was removed. He made a slow and uneventful recovery and was discharged to an extended care facility after a total duration of 43 days in our hospital.

Discussion

Malposition of feeding tubes is relatively common (1,2). Given that the tubes are small, relatively flexible and blindly inserted this is not surprising. In a series of more than 2000 insertions, Sorokin and Gottlieb (1) reported a 2.4% rate of lung insertion while de Aguilar-Nascimento and Kudsk (2) found a 3.2% incidence of lung malposition. Most malpositions occurred in the intensive care unit with 95% of the patients having an abnormal mental status and more than half with an endotracheal tube. Therefore, our patient was typical of the patient prone for feeding tube malposition.

To prevent feeding tube malposition, many hospitals insert the tubes under fluoroscopic guidance (3). Perhaps more commonly, other hospitals require radiographic confirmation before beginning feeding (1,2) . The later is the policy at our hospital, but as this case illustrates, mishaps can occur even with this safeguard.

In our case, several errors were made leading to the adverse event. Although recorded at the same time, the initial abdominal films were actually taken at different times. The patient had pulled his first feeding tube and a second tube had been inserted by the ICU nurse into the lung. The medicine house officer who read the films was not informed that two films were taken and saw the tube below the diaphragm on the first film. The house officer missed the tube in the chest on the second film. However, on this and three subsequent films, all read by separate radiologists, the tube malposition was also not identified. It can be difficult with multiple densities, from chest cardiac leads, suction tubing, intravenous tubing, etc. to identify potentially misplaced feeding tubes.

Generally, feeding tube malposition is reasonably well tolerated although aspiration and pneumothorax may result (1-3). Removal of the tube usually results in little apparent clinical harm. Our case is unusual in that an enteral feeding formula was introduced into the pleural space. Although there are previous reports of pneumothorax complication feeding tube insertion, these are relatively uncommon and we were uncertain how to proceed (4).  Eventually we decided on video assisted thoracic surgery with removal of any residual fluid. In this case the patient made an uneventful but prolonged recovery.  

When a feeding tube is in the lung, it may or may not have punctured the pleura. If it has, as was clear in this case by the course it took, (multiple loops), the chance of a pneumothorax on removal may be high. It is a matter of opinion as to whether or not in this situation; a prophylactic chest tube should be placed prior to removal of the feeding tube. In this case, this was performed as he was on mechanical ventilation. In situations where the feeding tube is clearly in a mainstem bronchus, removal is probably safe without due concern for a pneumothorax.

The errors in the formal radiology readings may be reduced by inverting the images within the radiology viewing program, and making sure that the full course of the feeding tube from oropharynx to tip is noted. In some obese patients, such as this one, an abdominal x-ray and chest x-ray may be required to do this.

References

1. Sorokin R, Gottlieb JE. Enhancing patient safety during feeding-tube insertion: a review of more than 2,000 insertions. JPEN J Parenter Enteral Nutr 2006;30:440-5.

2. de Aguilar-Nascimento JE, Kudsk KA. Clinical costs of feeding tube placement. JPEN J Parenter Enteral Nutr 2007;31:269-73.

3. Huerta G, Puri VK. Nasoenteric feeding tubes in critically ill patients (fluoroscopy versus blind). Nutrition 2000;16:264-7.

4. Wendell GD, Lenchner GS, Promisloff RA. Pneumothorax complicating small-bore feeding tube placement . Arch Intern Med 1991;151:599-602.

Page 1 ... 36 37 38 39 40